Search research articles
Contact Us
Filters
Showing results (771-780 of 797) with videos related to
Page
of 80
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 3, 2025
Pathological response calculation assessment remains accurate with reduced tumor bed examination after neoadjuvant immunotherapy in clinically detectable stage III melanoma
R V Rawson, N G Maher, A M Menzies, et al.
Nature Communications
|
April 17, 2020
Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma
Akash Mitra, Miles C Andrews, Whijae Roh, et al.
Nature Communications
|
July 9, 2022
Multi-modal molecular programs regulate melanoma cell state
Miles C Andrews, Junna Oba, Chang-Jiun Wu, et al.
Nature Medicine
|
April 22, 2024
Author Correction: Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results
Isabella C Glitza Oliva, Sherise D Ferguson, Roland Bassett, et al.
The Lancet. Oncology
|
January 24, 2018
Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial
Rodabe N Amaria, Peter A Prieto, Michael T Tetzlaff, et al.
Nature Medicine
|
March 30, 2023
Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results
Isabella C Glitza Oliva, Sherise D Ferguson, Roland Bassett, et al.
Nature Medicine
|
October 27, 2018
Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
Rodabe N Amaria, Sangeetha M Reddy, Hussein A Tawbi, et al.
Nature
|
March 9, 2023
Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma
Rodabe N Amaria, Michael Postow, Elizabeth M Burton, et al.
Nature
|
October 26, 2022
Neoadjuvant relatlimab and nivolumab in resectable melanoma
Rodabe N Amaria, Michael Postow, Elizabeth M Burton, et al.
Nature Medicine
|
October 10, 2018
Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
Rodabe N Amaria, Sangeetha M Reddy, Hussein A Tawbi, et al.
Page
of 80
Search research articles
Search
Showing results (771-780 of 797) with videos related to
Sort By:
Page
of 80
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 3, 2025
Pathological response calculation assessment remains accurate with reduced tumor bed examination after neoadjuvant immunotherapy in clinically detectable stage III melanoma
R V Rawson, N G Maher, A M Menzies, et al.
Nature Communications
|
April 17, 2020
Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma
Akash Mitra, Miles C Andrews, Whijae Roh, et al.
Nature Communications
|
July 9, 2022
Multi-modal molecular programs regulate melanoma cell state
Miles C Andrews, Junna Oba, Chang-Jiun Wu, et al.
Nature Medicine
|
April 22, 2024
Author Correction: Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results
Isabella C Glitza Oliva, Sherise D Ferguson, Roland Bassett, et al.
The Lancet. Oncology
|
January 24, 2018
Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial
Rodabe N Amaria, Peter A Prieto, Michael T Tetzlaff, et al.
Nature Medicine
|
March 30, 2023
Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results
Isabella C Glitza Oliva, Sherise D Ferguson, Roland Bassett, et al.
Nature Medicine
|
October 27, 2018
Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
Rodabe N Amaria, Sangeetha M Reddy, Hussein A Tawbi, et al.
Nature
|
March 9, 2023
Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma
Rodabe N Amaria, Michael Postow, Elizabeth M Burton, et al.
Nature
|
October 26, 2022
Neoadjuvant relatlimab and nivolumab in resectable melanoma
Rodabe N Amaria, Michael Postow, Elizabeth M Burton, et al.
Nature Medicine
|
October 10, 2018
Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
Rodabe N Amaria, Sangeetha M Reddy, Hussein A Tawbi, et al.
Page
of 80